New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:16 EDTEWEdwards receives CE Mark for advances SAPIEN 3 value
Edwards Lifesciences announced that it has received CE Mark in Europe and is initiating the launch of its most advanced transcatheter aortic valve, the Edwards SAPIEN 3 valve. The SAPIEN 3 valve builds upon Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve has an outer skirt -- a cuff of fabric surrounding the valve frame -- providing a seal to address paravalvular leak. The effectiveness of this solution is supported by the limited clinical experience, as detailed in two first-in-human feasibility studies, which demonstrated that significant paravalvular leak was eliminated during transcatheter aortic valve implantation. The SAPIEN 3 valve is the only commercial transcatheter heart valve that can be delivered through a low-profile 14 French expandable sheath, which has shown through early clinical experience a low rate of complications. The valve can be implanted through multiple approaches: transfemoral, transapical or transaortic. Once implanted, the discreet valve anchors in the aortic annulus. In the United States, the Edwards SAPIEN 3 valve is an investigational device being studied in the PARTNER II Trial and is not yet available for sale in the country.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
11:40 EDTEWEdwards Lifesciences mentioned positively by Navellier
Subscribe for More Information
October 27, 2014
07:23 EDTEWAmerican College of Surgeons holds a conference
Subscribe for More Information
October 24, 2014
12:49 EDTEWOn The Fly: Midday Wrap
Stocks on Wall Street opened relatively quietly, with investors cautious given the way the market closed yesterday following the report a NYC doctor had the Ebola virus. As the morning progressed investors became more emboldened and pushed the market higher, leaving the major averages near their highs at midday. ECONOMIC EVENTS: In the U.S., a report on new home sales showed that they inched up 0.2% to a 467K rate in September, but August was revised much lower. COMPANY NEWS: Shares of Amazon (AMZN) fell 7.5% after the company reported weaker than expected results and provided lower than expected revenue guidance. At least two analysts downgraded the stock following its report, while a number of others cut their price targets on the shares... Procter & Gamble (PG) rose 3% after the company's Q1 core EPS matched estimates and it announced plans to exit the Duracell personal power business. P&G noted that while no decision has been made on the form of the exit, the company’s current preference is a split-off of the Duracell business into a stand-alone company. MAJOR MOVERS: Among the notable gainers was were Edwards Lifesciences (EW), which rose 11% following the company's "beat and raise" report. Also higher was SodaStream (SODA), which jumped 14% after confirming that it has entered into an agreement with PepsiCo (PEP) specifically focused on a small-scale, limited time test to make certain of PepsiCo’s brands available for use on the company’s at-home beverage system. Among the noteworthy losers was Pandora (P), which dropped 15% after reporting quarterly results that included a sequential drop in listener hours. Also lower was Abercrombie & Fitch (ANF), which fell 5.5% after Goldman Sachs downgraded the stock to a Sell rating in a note to investors. INDEXES: Near midday, the Dow was up 86.67, or 0.52%, to 16,764.57, the Nasdaq was up 16.36, or 0.37%, to 4,469.15, and the S&P 500 was up 8.86, or 0.45%, to 1,959.68.
08:37 EDTEWEdwards Lifesciences price target raised to $132 from $100 at Stifel
Stifel increased its price target on Edwards as the firm believes that the company's Q3 results were "outstanding." The firm thinks the TAVR market has a number of very visible and positive global rivers, while the stock has a number of potential positive catalysts. The firm keeps a Buy rating on the shares.
October 23, 2014
16:21 EDTEWEdwards Lifesciences raises FY14 EPS $3.33-$3.39, consensus $3.30
Sees FY 14 revenue higher than previous $2.05B-$2.25B, consensus $2.24B.
16:19 EDTEWEdwards Lifesciences sees Q4 EPS 89c-95c, consensus 95c
Sees Q4 revenue $575M-$615M, consensus $586.91M.
16:15 EDTEWEdwards Lifesciences reports Q3 EPS 80c, consensus 73c
Reports Q3 revenue $607.4M, consensus $546.32M.
15:30 EDTEWNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use